Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690123 | 1.00 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL28261353 | 0.85 | HTR6 (0.41) | MEN1KMT2A | |
| SCHEMBL13979443 | 0.85 | HTR2A (0.39) | MEN1KMT2A | |
| SCHEMBL28261355 | 0.81 | DDB1 (0.39) | MEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL31122360 | 0.81 | HTR2A (0.44) | MEN1KMT2A | |
| SCHEMBL31122364 | 0.81 | HTR2A (0.44) | MEN1KMT2A | |
| SCHEMBL24055884 | 0.81 | ALDH1A1 (0.33) | — | |
| SCHEMBL29639145 | 0.80 | SLC6A2 (0.45) | — | |
| SCHEMBL4430948 | 0.79 | MEN1 (0.40) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL22812897 | 0.79 | DRD1 (0.40) | MEN1CYP3A4CYP2D6KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | claimed |
| CN-113200998-B | Organic luminescent material and application thereof | 武汉市晟承宇科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-113173934-B | Organic compound, application thereof and organic electroluminescent device | 武汉市晟承宇科技有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-113004261-B | Compound containing multi-heterocyclic structure and application thereof | 北京云基科技股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-111909171-B | Electron transport material and application thereof | 北京燕化集联光电技术有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-112778312-B | Organic material containing indoloquinazolinedione heterocyclic structure and application thereof | 北京燕化集联光电技术有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-114628466-A | Display device | 三星显示有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114380807-A | Light-emitting element and amine compound for light-emitting element | 三星显示有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-111662309-B | Compound with multi-heterocyclic structure and application thereof | 北京燕化集联光电技术有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-111662309-A | Compound with multi-heterocyclic structure and application thereof | 北京燕化集联光电技术有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-8230986-B2 | Torque limiter | JTEKT CORPORATION (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8220609-B2 | Torque limiter | JTEKT CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100184519-A1 | TORQUE LIMITER | JTEKT CORPORATION (JP) | 2010-07-22 | — | — | US | disclosed |
| US-20090173591-A1 | TORQUE LIMITER | JTEKT CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-2009304-A1 | TORQUE LIMITER | JTEKT Corporation (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2003353-A1 | TORQUE LIMITER | JTEKT Corporation (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20070123491-A1 | Podophyllotoxin derivatives as igf-1r inhibitors | BIOVITRUM AB (SE) | 2007-05-31 | — | — | US | disclosed |
| EP-1615932-A2 | PODOPHHYLLOTOXIN DERIVATIVES AS IGF-1R INHIBITORS | Biovitrum AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | disclosed |
| WO-2004093781-A2 | PODOPHYLLOTOXIN DERIVATIVES AS IGF-1R INHIBITORS | BIOVITRUM AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | PDE3A, PDE3B, PDE12 | MEN1 3117/4885CYP3A4 417/4885CYP2D6 1067/4885 |
| US-20070123491-A1 | Podophyllotoxin derivatives as igf-1r inhibitors | IGF1R, IGFBP1, INSR | MEN1 382/4885CYP3A4 4629/4885CYP2D6 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.